IGC Receives a Notice of Allowance from the U.S. Patent Office
July 20 2020 - 7:00AM
Business Wire
India Globalization Capital, Inc. (the “Company”) (NYSE
American: IGC) recently received a Notice of Allowance dated July
8, 2020 from the United States Patent and Trademark Office
(“USPTO”) for the Company’s cannabinoid formulation for the
treatment of seizures in humans and veterinary animals. IGC filed
this application for its IGC-502 formulation and method
(#15/104,556) on June 15, 2016. The USPTO issues a Notice of
Allowance if, after examination by a patent examiner, it appears
that the applicant is entitled to a patent under the law. The
actual issuance of the patent could take several months and
requires that the Company undertake certain steps, including the
payment of fees. The Company plans to pursue patent issuance.
Forward-looking Statements:
This press release contains forward-looking statements within
the meaning of Section 21E of the Securities Exchange Act of 1934.
These forward-looking statements are based largely on IGC’s
expectations and are subject to a number of risks and
uncertainties, certain of which are beyond IGC’s control. Actual
results could differ materially from these forward-looking
statements as a result of, among other factors, worsening of the
COVID-19 outbreak in China, the U.S., and other parts of the world,
the prolonged continuation of travel restrictions related to the
outbreak, continued disruption of the Hong Kong economy,
competitive conditions in the industries in which IGC operates,
failure to meet operational goals and/or revenue and profit targets
products in various stages of production and commercialization,
failure to commercialize one or more of the products or
technologies of IGC, including any products or patented
formulations identified herein, or the failure or inability to pay
patent maintenance fees, potential rejection of any patent
application even when the Company is in compliance with USPTO
requirements, any changes in federal, state, or local law
applicable to our businesses and the locations where we operate,
general economic, political, and health and welfare conditions that
are less favorable than expected, the Federal Food and Drug
Administration’s (FDA) general position regarding hemp-based and
related products in particular, and other factors, many of which
are discussed in our SEC filings. The Risk Factors identified in
the Company’s annual report, filed on Form 10-K with the SEC on
July 13, 2020, and in the Company’s quarterly reports, filed on
Form 10-Q with the SEC on November 5, 2019 and February 10, 2020,
are incorporated herein by reference. In light of these risks and
uncertainties, there can be no assurance that the forward-looking
information contained in this release will in fact occur.
About IGC:
IGC has two lines of business: infrastructure and life sciences,
including hemp-derived medical cannabis/industrial hemp. The
company is based in Maryland, U.S.A. Our website:
www.igcpharma.com, www.igcinc.us. Twitter @IGCIR
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200720005110/en/
Claudia Grimaldi 301-983-0998
IGC Pharma (AMEX:IGC)
Historical Stock Chart
From Aug 2024 to Sep 2024
IGC Pharma (AMEX:IGC)
Historical Stock Chart
From Sep 2023 to Sep 2024